Search Results

Bosutinib

Bosutinib is FDA approved for the treatment of

Adult and pediatric patients 1 year of age and older with chronic phase Ph+ chronic myelogenous leukemia (CML), newly diagnosed or resistant or intolerant to prior therapy.
Adult patients with accelerated, or blast phase Ph+ CML with resistance or intolerance to prior therapy.

Inqovi is FDA approved for treatment of adult patients with myelodysplastic syndromes (MDS), including previously treated and untreated, de novo and secondary MDS with the following French American-British subtypes (refractory anemia, refractory anemia with ringed sideroblasts, refractory anemia with excess blasts, and chronic myelomonocytic leukemia [CMML]) and intermediate-1, intermediate-2, and high-risk International Prognostic Scoring System groups.

Avapritinib

Ayvakit® is indicated for the treatment of

When The Time Comes: Katie & Phil’s Story

Breaking Down Barriers in Blood Cancer Care

All patients deserve quality cancer care that's within reach

LLS and volunteers cheer California laws promoting health equity

BURLINGTON STORES AND THE LEUKEMIA & LYMPHOMA SOCIETY CONTINUE THEIR PARTNERSHIP IN THE FIGHT AGAINST BLOOD CANCER

The Leukemia & Lymphoma Society Names Lore Gruenbaum, Ph.D., New Chief Scientific Officer

Research Funded by The Leukemia & Lymphoma Society Among Highlights at Annual American Society of Hematology

Louis J. DeGennaro, Ph.D., Named President and Chief Executive Officer of The Leukemia & Lymphoma Society

The Leukemia & Lymphoma Society’s Light The Night Events Lead the Charge Against Blood Cancer

The Leukemia & Lymphoma Society Awards $65 Million in New Funding for Blood Cancer Research

The Leukemia & Lymphoma Society Honors Five Outstanding Blood Cancer Scientists with 2023 Awards

The Leukemia & Lymphoma Society’s Illinois Chapter Announces Local 2020 Students of the Year Winner

Suggested Reading - Childhood Leukemia Guide for Families, Friends and Caregivers, 5th ed.

By Nancy Keene
Childhood Cancer Guides, 2018, 496 pages
ISBN: 978-1-941089-04-0

This most complete parent guide provides accurate and understandable medical information about leukemia and the various treatment options, as well as day-to-day practical advice on how to cope with procedures, hospitalization, family and friends, school, social and financial issues, and communicating with healthcare providers. Reviewed by distinguished experts in pediatric oncology, Childhood Leukemia includes practical and poignant stories from more than 175 parents, children with leukemia, and their siblings. This book helps families cope––one day at a time.

For more information click here

Audience

Adults

Subject

Coping

New Series-Research Highlight: Acute Lymphoblastic Leukemia-New Targets, Pathways and Therapies

Subaru Partners With The Leukemia & Lymphoma Society For Ninth Year Supporting Patients Facing Cancer

Leukemia Survivor Named National ‘Visionary of the Year’ Redefining What’s Possible After Diagnosis

Wawa and The Leukemia & Lymphoma Society Celebrate a Decade of Impact During National Volunteer Week

The Leukemia & Lymphoma Society Named in Fast Company’s Second Annual List of “Brands That Matter”

The Leukemia & Lymphoma Society Receives Grant Award from Disabled Veterans National Foundation

Filgrastim-sndz

Filgrastim-sndz is FDA approved as a biosimilar to US-licensed Neupogen® for the five indications for which Neupogen is approved:

Patients with cancer receiving myelosuppressive chemotherapy;
Patients with acute myeloid leukemia receiving induction or consolidation chemotherapy;
Patients with cancer undergoing bone marrow transplantation;
Patients undergoing autologous peripheral blood progenitor cell collection and therapy; and
Patients with severe chronic neutropenia.